Antineoplastic Combined Chemotherapy Protocols

SEP 2, 2026 · JOURNAL ARTICLE

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.

Oncoimmunology

Early-phase single-arm trial terminated early due to slow accrual with only 13 enrolled patients, showing limited clinical benefit (8.3% response rate) but providing mechanistic insights into immune response that warrant further investigation.

AUG 5, 2026 · JOURNAL ARTICLE

Comparative safety profiles of antibody-drug conjugates: a real-world analysis of monotherapy and combination regimens in solid tumors.

Drug Delivery

Large real-world pharmacovigilance study of 19,697 adverse event reports confirms known structure-toxicity relationships for ADCs, but lacks comparative efficacy data and uses observational methods without prospective controls.

JUL 28, 2026 · JOURNAL ARTICLE

Estimating the cost-effectiveness of tumor treating fields for locally advanced pancreatic cancer patients.

Journal of Medical Economics

Cost-utility analysis of a novel cancer therapy showing incremental QALY gain with high ICER; confirms clinical benefit translates to measurable quality-of-life improvement but at costs above conventional thresholds.

JUL 22, 2026 · JOURNAL ARTICLE

Interim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study.

Annals of Medicine

Retrospective multicenter study showing high response rates and 2-year survival outcomes for a high-risk CD5+ DLBCL population treated with Pola-R-CHP, with interim PET response predicting survival, but limited by small sample size, retrospective design, and short median follow-up.